iadademstat   Click here for help

GtoPdb Ligand ID: 8390

Synonyms: ORY-1001 | ORY1001 | RG-6016
Compound class: Synthetic organic
Comment: Iadademstat (ORY-1001; Oryzon Genomics) is a selective and irreversible inhibitor of lysine (K)-specific demethylase 1A (KDM1A, aka LSD1) [2]. Structurally it is a derivative of tranylcypromine. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumour suppressor genes. ORY-1001 is claimed in patent WO2010084160A1 [1]. We provide the structure for the parent compound and the dichloride salt is represented in PubChem CID 71664305.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 38.05
Molecular weight 230.18
XLogP 2.27
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC1CCC(CC1)NC1CC1c1ccccc1
Isomeric SMILES NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1
InChI InChI=1S/C15H22N2/c16-12-6-8-13(9-7-12)17-15-10-14(15)11-4-2-1-3-5-11/h1-5,12-15,17H,6-10,16H2/t12?,13?,14-,15+/m0/s1
InChI Key ALHBJBCQLJZYON-PFSRBDOWSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Iadademstat (ORY-1001) was progressed as a clinical candidate, for potential to treat leukemias or advanced small cell lung cancer. It was designated as an 'orphan-medicinal-product' for the treatment of acute myeloid leukemia (AML) by the EMA in 2013.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05546580 Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) Phase 1 Interventional Oryzon Genomics S.A.
NCT06287775 Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer Phase 1/Phase 2 Interventional National Cancer Institute (NCI)
NCT06661915 A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Phase 2 Interventional National Cancer Institute (NCI)